Best Life Sciences Companies in Abingdon, United Kingdom
The 31 best Life Sciences companies in Abingdon, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunocore.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Abingdon
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunocore Developer of bispecific T cell receptor therapies for human diseases | $525M | 51 mo ago | 293 293 → 604 (+106%) | Nicholas Cross Co-Founder | Public | 776 patents TCR-based bispecific immunotherapies targeting peptide‑MHC complexes for cancer treatment | — |
| 2 | Oxford Immunotec Commercial-stage diagnostics company using immune markers to diagnose disease | $94M | 106 mo ago | 184 | — | Acquired | 40 patents Immunodiagnostic assays for TB, COVID-19, and microbial protein fragment screening | — |
| 3 | Oxagen Developer of drugs for inflammatory and respiratory diseases | $86M | 203 mo ago | 3 | Richard Edwards Managing Director | Deadpooled | 151 patents CRTH2 receptor antagonist pharmaceutical compounds for treating inflammatory and allergic diseases | — |
| 4 | Sense Biodetection Provider of point of care molecular diagnostics solutions | $79M | 59 mo ago | 43 | — | Acquired | 82 patents Rapid nucleic acid diagnostic assays with integrated heating modules for point‑of‑care testing | — |
| 5 | Chroma Therapeutics Small molecule drugs based on chromatin biology and cell accumulation for targeted cancer and inflammation… | $78M | 208 mo ago | 51 | Richard Bungay CEO | Deadpooled | 303 patents Small-molecule kinase inhibitors for inflammatory, autoimmune and cancer therapies | — |
| 6 | Accession Therapeutics Developer of therapeutics for cancer treatment | $66M | 30 mo ago | 4 | Francis Yuan Co-Founder | Series B | — | — |
| 7 | Emergex Vaccines Developer T-cell Vaccines for treating viral and bacterial infections | $30M | 56 mo ago | 19 | Storme Moore-Thornicroft Co-Founder | Series A | 89 patents Peptide-based vaccine design targeting coronavirus and flavivirus epitopes for immunotherapy | — |
| 8 | Glide Technologies Specialty company developing drug delivery products | $29M | 117 mo ago | 22 | — | Series B | — | — |
| 9 | GlySure Continuous glucose monitoring using optical fluorescence sensor | $24M | 167 mo ago | 41 | — | Series C | 23 patents Optical fiber fluorescence-based intravascular continuous glucose monitoring and calibration | — |
| 10 | Midatech Provider of novel drug delivery technologies for the treatment of diseases | $16M | 45 mo ago | 40 40 → 24 (-40%) | — | Public | 204 patents Targeted cyclodextrin and nanoparticle drug delivery systems for oncology and inflammation | — |
| 11 | Celleron Therapeutics Developing drugs targeting epigenetic control for the treatment of cancer. | $16M | 117 mo ago | 11 | Nick Thangue CEO | Series B | — | — |
| 12 | Orthox Developer of devices for cartilage and tissue treatment | $12M | 52 mo ago | 22 | Nick Skaer Founder & CEO | Series A | 43 patents Implantable tissue repair scaffolds and manufacturing processes for orthopedic regeneration | — |
| 13 | Karus Therapeutics Developer of oral small molecule inhibitors to treat multiple diseases | $8M | 170 mo ago | 8 | — | Deadpooled | 219 patents Novel heterocyclic PI3K and HDAC inhibitors for targeted cancer therapies | — |
| 14 | Atopix Therapeutics Medicines to treat atopic dermatitis and severe asthma | $6M | 136 mo ago | 6 | Ugo Francesco CEO | Acquired | 104 patents Novel small‑molecule therapeutics and polymorphic forms for oncology/immune modulation | — |
| 15 | GeneFirst Developer of PCR technologies in the fields of cancer diagnostics and personalised medicine | $5M | 98 mo ago | 10 10 → 10 (+0%) | Guoliang Fu Founder & CEO | Funding Raised | 35 patents Nucleic acid library preparation and targeted sequencing kit technologies | — |
| 16 | Orca Pharmaceuticals Develops oral drugs for the treatment of chronic inflammatory diseases | $4M | 147 mo ago | 2 | Michael Hunter Founder | Series A | 9 patents Small-molecule RORγt inhibitors for treating autoimmune and inflammatory diseases | — |
| 17 | Matoke Holdings Developing reactive oxygen technology for microbial infection treatment | $3M | 31 mo ago | — | Ian Staples Founder & CEO | Seed | 105 patents Antimicrobial pharmaceutical formulations and medical device coatings for infection control | — |
| 18 | Oxford BioTherapeutics Develop antibody drug conjugates (ADCs) to treat cancer | $3M | 99 mo ago | 21 | Bernd Seizinger Chairman | Series B | 311 patents Antibody‑drug conjugates targeting LY75/CD205 for cancer immunotherapy | — |
| 19 | Active Needle Developer of medical devices for ultrasound-guided interventional procedures | $1M | 60 mo ago | 2 | Ian Quirk CEO and Founder | Seed | 36 patents Needle-based injection and tattoo delivery devices with specialized cartridge mechanisms | — |
| 20 | Abgentis UK-based, early-stage biopharma developing small molecule DNA coiling inhibitors against drug resistant… | $121K | 152 mo ago | 2 | — | Seed | — | — |
Top 12 Life Sciences companies in Abingdon
#1
Series B · Abingdon, England · founded 2020 · 4 employees$66.1Mraised▾
Developer of therapeutics for cancer treatment. The company offers immunotherapy based on proprietary technology that incorporates cancer-tropic viruses to target cancer cells. The therapy kills all cancer cell variants and activates the full immune system arsenal local to the tumour.
- Apr 2024Series B$31.3M
- Nov 2022Series A$19.7M
- Sep 2021Seed$15M
#2
Public · Abingdon, England · founded 2008 · 293 employees$525Mraised▾
Developer of bispecific T cell receptor therapies for human diseases. These biological medicines utilize modular technology to modulate immune system activity. The therapies target diseased cells to facilitate destruction or reduce immune responses in patients with cancer, infectious diseases, and autoimmune conditions. The research and development process focuses on creating treatments that interact with the human leukocyte antigen system to address unmet medical needs.
- Jul 2022Post IPO$140M
- Feb 2021Post IPO$15M
- Jan 2021Series C$75M
- Jan 2021Conventional Debt$100M
#3
Seed · Abingdon, England · founded 2010$3.3Mraised▾
Matoke Holdings is developing reactive oxygen technology for microbial infection treatment. The reactive oxygen species-mediated vasoconstriction induces thrombus formation that helps in the rapid migration of blood vessels towards the injury site and helps in tissue repair.
- Mar 2024Seed$500K
- Jun 2023Seed$212.5K
- Jun 2023Seed$500K
- Apr 2023Seed$110.5K
#4
Public · Abingdon, England · founded 2000 · 40 employees$16Mraised▾
Provider of novel drug delivery technologies for the treatment of diseases. It develops a pipeline of product candidates in clinical and pre-clinical development for diseases such as diabetes, rare cancers including brain, ovarian, liver, and pancreatic cancer, and neurological/ophthalmologic conditions. It provides in-house technology platforms for sustained release to prolong and control the release of therapeutics over an extended period of time and dissolve insoluble drugs which can be converted into liquid form and can be treated for tumor patients.
- Feb 2023Post IPO$6M
- Aug 2020Post IPO$1M
- 2020Grant (prize money)$56.1K
- Oct 2019Post IPO$3M
#5
Acquired · Abingdon, England · founded 2014 · 43 employees$79.2Mraised▾
Provider of point of care molecular diagnostics solutions. The company has Veros platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. It commercialize Veros COVID-19 test, which delivers laboratory results directly to users.
- Nov 2021Series B$15M
- Apr 2021Series B$50M
- Oct 2020Series B—
- Oct 2019Grant (prize money)$2.3M
#6
Series A · Abingdon, England · founded 2016 · 19 employees$30Mraised▾
Emergex Vaccines is developing T-cell vaccines for treating viral and bacterial infections. The company targets mainly Zika, Ebola, pandemic flu, and antibiotic-resistant bacteria. The technology delivers immunogenic peptides which result in T-cell immune response. The lead candidate of the company, EMX-001, which is a flavivirus vaccine. It is used to treat zika, dengue, and yellow fever. The candidate is in the preclinical stage.
- Feb 2022Grant (prize money)$667.7K
- Nov 2020Series A$11M
- Jan 2020Series A$11M
- Nov 2018Series A$4.3M
#7
Series A · Abingdon, Oxfordshire · founded 2008 · 22 employees$12.5Mraised▾
Developer of devices for cartilage and tissue treatment. It offer FibroFix Cartilage implants to repair and regenerate the tough, shock absorbing meniscal cartilage in the knee. It is based on Fibroin, a protein extracted from silk fibres for repairing cartilage tissue.
- Jun 2022Grant (prize money)$52.4K
- Feb 2022Series A$12.5M
- Jul 2020Grant (prize money)—
- Jul 2020Grant (prize money)$2.6M
#8
Acquired · Abingdon, England · founded 2002 · 184 employees$94Mraised▾
Oxford Immunotec is a commercial-stage diagnostics company using immune markers to diagnose disease. The company has a proprietary platform T-SPOT technology that measures immune cell responses at a single-cell level. It also offers tests for tuberculosis and cytomegalovirus (CMV), and also for assessing the risk of organ rejection in transplant patients.
- Jan 2018Grant (prize money)$325.9K
- Jun 2012Series E$28M
- May 2010Series D$26M
- Oct 2007Series C$40M
#9
Deadpooled · Abingdon, England · founded 2000 · 51 employees$77.5Mraised▾
Chroma Therapeutics is focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. It aims to build innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders. Its lead candidate is Tosedostat (aminopeptidase inhibitor) to treat haematological tumors (AML) and solid tumors. Also developing drugs to inhibit Histone deacetylases (HDAC).
- Jun 2009Series D$24.5M
- Apr 2006Series C$53M
#10
Series B · Abingdon, England · founded 2001 · 22 employees$29.1Mraised▾
Glide Technologies is a specialty pharmaceutical company developing products for easy, safe and convenient delivery of pharmaceuticals and vaccines on its proprietary Glide SDI - the Solid Dose Injector. The company has a portfolio of 5 pipeline products, all of which are focused on developing a solid dosage formulation of existing drugs for higher stability and better drug delivery.
- Feb 2017Series B$4M
- Feb 2013Series B$21.4M
- Nov 2012Grant (prize money)$3.7M
- Oct 2008Series A$3.7M
#11
Deadpooled · Abingdon, England · founded 1997 · 3 employees$86.5Mraised▾
Developer of drugs for inflammatory and respiratory diseases. The company develops drugs for the treatment of asthma, autoimmune disease, inflammatory bowel, psoriasis, allergy, and rheumatoid arthritis diseases. The company is currently developing OC000459 which is an oral CRTH2 antagonist, used in the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. It has provided Eleventa rights to commercialize OC000459 in Russia and CIS and has partnered with Atopix Therapeutics to commercialize OC000459 in the rest of the world
#12
Seed · Abingdon, England · founded 2016 · 2 employees$1.2Mraised▾
Developer of medical devices for ultrasound-guided interventional procedures. The company offers Bright-line that uses hand-held piezoelectric core biopsy needle provides unrivalled visualisation during ultrasound guidance in colour Doppler to induce minute longitudinal ultrasonic vibrations and enables precision needle targeting.
- Oct 2021Seed$525.3K
- Mar 2020Seed$246.6K
- Mar 2017Angel$427.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United Kingdom
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,508 United Kingdom-affiliated papers.
- Imperial College London70
- University College London67
- University of Cambridge54
- University of Edinburgh54
- University of Oxford48
- Gene4→31
- Population1→15
- Mutation1→13
- Chromatin1→11
- Mutant2→12
- Gene2→35
- Antimicrobial1→22
- Bacteria1→17
- Downregulation and upregulation1→17
- Antibody3→19
- Production (economics)3→14
- Antimicrobial4→14
- Agriculture9→18
- Sustainability1→10
- Food safety2→11
Where biotechnology is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United Kingdom
United Kingdom biotechnology patent filing is accelerating — 35,956 filings from 8,000 assignees (2016–2025), led by Medimmune, Glaxo Group, UCL Business; annual filings 2688→3463.
- Medimmune2938
- Glaxo Group1582
- UCL Business1575
- UNIV Oxford Innovation1145
- Glaxosmithkline IP DEV997
- Medical RES Council945
- Cambridge Entpr859
- Kymab850
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.